



Press Release

MSN Laboratories Initiates Phase III Clinical Trial of Molnupiravir for India

Hyderabad, 25 May 2021: MSN Laboratories Pvt. Ltd. (MSN), the front-runner in introducing various drugs in the treatment of Covid-19 and its complications, post its launch of Posaone (Posacanazole) tab & IV in the treatment of black fungus, announced today that MSN is initiating phase III clinical trial of Molnupiravir capsules for the treatment of Covid-19 in India.

MSN has received its clinical trial approval on 19th May 2021, from Drug Controller General of India's to perform Molnupiravir Capsules efficacy and safety study on Mild to Moderate COVID-19 patients. MSN will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon. The clinical trials will be performed on more than 2400 subjects suffering from mild to moderate COVID-19.

Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for COVID treatment. MSN R&D team has developed both the API and Formulation, is expecting to launch soon after successful conclusion of clinical study followed by regulatory approval.

As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules and licensed Baridoz (Baricitinib) recently with Eli Lilly. For availability of all COVID Drugs from MSN, patients can contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com for further assistance.

END



About MSN Group:

MSN Group is the fastest growing research based pharmaceutical company headquartered in India. Founded in 2003 with a mission to make health care affordable, MSN has nine API and five finished dosage facilities in Hyderabad and the U.S. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has achieved more than 650 national and international patents, over 100 ANDAs, is world no. 1 in active U.S. DMF filings, has a product portfolio featuring over 380 APIs and over 250 formulations covering over 35 major therapies and has won the trust of more than 40,000,000 customers across 65 countries worldwide.

www.msnlabs.com

Media Contact:

Karthik Chittoor Corporate Communications MSN Group of Companies Email: karthik.chittoor@msnlabs.com Phone no: 9030088669	Vishal Kumar Fortuna PR Email: vishal@fortunapr.com Phone no: 9885585802
--	--